growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in
the adjuvant treatment of high-grade astrocytomas
L, Miyamoto CT, Bender H, Brady LW, Steplewski Z, Class R, Emrich J, Rackover MA
of Radiation Oncology, Hahnemann University, Philadelphia, PA, USA
patients with primary presentation of high-grade gliomas of the brain, 13 with
astrocytomas with anaplastic foci and 46 with glioblastoma multiforme, were
treated with surgical intervention and definitive postoperative radiation
therapy followed by multiple intravenous administration of iodine-125-labeled
monoclonal antibody-425, which binds specifically to human epidermal growth
The total cumulative labeled antibody doses ranged from 40 to 296 mCi.
The administration of the radiolabeled antibody was performed in most instances
within 3 months following completion of the primary surgery and radiation
No significant life-threatening toxicities were observed during the trial.
At one year, 34 (58%) of the 59 patients in the trial were alive.
The median overall survival for both groups was 13.5 months.
7590764 [PubMed - indexed for MEDLINE]